Methods PEMMELA was a prospective single-center, single-arm, open-label, investigator-
initiated phase 2 trial of pembrolizumab (200 mg once every three weeks intravenously) plus …

Background The combination of pembrolizumab, an anti-PD-1 antibody, and lenvatinib, an
antiangiogenic multikinase inhibitor, shows synergistic activity in preclinical and clinical …

Background Malignant pleural mesothelioma (MPM) is a highly aggressive cancer with poor
prognosis and limited treatment options after progression on platinum-containing …

Background: The programmed death receptor 1 (PD-1) pathway is implicated in evasion of
the antitumor immune response. Pembrolizumab is a potent, highly selective humanized …

Background Pleural mesothelioma usually presents at an advanced, incurable stage.
Chemotherapy with platinum–pemetrexed is a standard treatment. We hypothesised that the …

Background Checkpoint inhibitor (CPI) therapies have demonstrated clinical benefit in
patients (pts) with malignant pleural mesothelioma (MPM) and are now included in the …

Methods Adult patients with previously untreated, unresectable, histologically confirmed
MPM and ECOG performance status 0–1 were randomized (1: 1; stratified by histology …

Background Malignant pleural mesothelioma (MPM) is an aggressive malignancy
characterised by limited treatment options and a poor prognosis. At relapse after platinum …

Introduction Studies of bevacizumab and pembrolizumab in the treatment of malignant
pleural mesothelioma suggest anticancer efficacy; clinical trial populations are not reflective …

Background: Available 2nd line chemotherapies for relapsed malignant pleural
mesothelioma (MPM) have limited activity. Results from early clinical trials-including the …